# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $...
Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) with a Hold.
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0...
Piper Sandler analyst Edward Tenthoff upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Overweight and raises the pri...